DONATE

Pau Gorostiza

Group leader

Three researchers from IBEC awarded with grants from “la Caixa” for their pioneering and high social impact research

José Antonio del Río, Pau Gorostiza, and Samuel Sánchez have been awarded in two of the “la Caixa” calls.

José Antonio del Río, principal investigator of the Molecular and Cellular Neurobiotechnology Group at IBEC, is one of the winners of the second edition of the call for applications in biomedicine and health. Del Río’s project focuses on analysing the molecular mechanisms involved in the genesis and propagation of tau protein in brain cells. This protein is linked with several neurodegenerative processes and is present in numerous diseases such as Alzheimer’s.

Pau Gorostiza, principal investigator of the Nanoprobes and Nanoswitches Group, also received an award at the second edition of the call for applications for research projects in biomedicine and health. In this case, for his project on degenerative eye conditions such as retinitis pigmentosa, which causes blindness due to the progressive degeneration of the cones and rods, which are the light sensitive cells.

Closer to a functional atlas of the brain

Scientists from the Institute for Bioengineering of Catalonia develop a technique that enables them to work out the specific function of a neuronal receptor according to its location in the brain. The study, published in PNAS, is based on the activation of photoswitchable drugs with micrometric precision and offers new opportunities in neurobiology.

Schizophrenia, depression, myasthenia… Many neurological diseases are due to the malfunctioning of a neuronal receptor. These proteins, also known as neuroreceptors, are responsible for sending and detecting neurotransmitters, chemical substances that allow communication between neurons.

ERC President visits IBEC

The President of the European Research Council, Jean-Pierre Bourguignon, visited last May 15th the Institute for Bioengineering of Catalonia (IBEC).

The event was inaugurated by IBEC’s Director, Josep Samitier, who presented an overview on the cutting-edge research carried out at the institute in the fields of bioengineering and nanomedicine.

Afterwards, ERC Grantees working at IBEC had the opportunity to explain the impact of ERC grants on their professional careers and established a dialogue with ERC President on the past, present and future of the European Research Council.

A new technique allows researchers to focus the action of drugs via infrared light

A scientific team led by IBEC and UAB manages to efficiently activate molecules located inside cell tissues using two-photon excitation of with infrared light lasers. The results of the study has been published in Nature Communications.

Having absolute control of the activity of a molecule in an organism. Deciding when, where and how a drug is activated. These are some of the goals expected to be reached with the so-called photoswitchable molecules, compounds that, in the presence of certain light waves, change their properties. Today, thanks to the results of a study led by the Institute for Bioengineering of Catalonia (IBEC) together with the Universitat Autònoma de Barcelona (UAB), the scientific community is one step closer to achieving this objective.

Proteins can transfer electrons at a distance

Collaborating IBEC groups have published a study in Nature Communications that reveals that electron transfer can take place while a protein is approaching its partner site, and not only when the proteins are engaged, as was previously thought.

The results open up a new way of thinking about how proteins interact, and can have implications in a better understanding of many processes – such as photosynthesis, respiration and detoxification – in which electron transfer plays an important role.

The relocation of an electron from one chemical entity to another – electron transfer (ET) – doesn’t happen passively: electrons are carried individually by redox proteins.

IBEC researchers uncover strategy to reduce chemotherapy side effects

Researchers at IBEC and IDIBELL have developed a light-regulated molecule that could improve chemotherapy treatments by controlling the activity of anticancer agents.

Chemotherapy – the use of cytotoxic agents to kill the rapidly proliferating cells in tumors – is one of our main tools in the fight against cancer. However, its effectiveness and the body’s tolerance of it is often dramatically limited: it can affect healthy areas rather than just the cancerous ones, which causes side effects.

Molecules activated by light to control glutamate receptors

immunoliposomes Researchers at IBEC, IQAC-CSIC and CNRS have developed molecules that can modulate the activity of glutamate receptors in the central nervous system, with important applications in biomedicine.

For the last few years the collaborators have been working on the development of molecules called targeted covalent photoswitches (TCPs), whose structure can be changed using light. This change in shape causes the molecule to be recognized – or not – by a biological receptor as a key is to a lock. This coupling activates the receptor or not, triggering the activity.

Celebrating advances in spinal cord and brain research by Marató-funded projects

pgorostiza_allobet_IBEC group leader and ICREA research professor Pau Gorostiza took part in the 17th Symposium of La Marató de TV3 this week, which was devoted to the celebration of the 30 research projects awarded funding by the telethon in 2010.

The event at the Institut d’Estudis Catalans on Wednesday, which included a poster session open to the public, featured round tables of experts discussing the findings of the projects, which covered research into the understanding, treatment and prognosis acquired spinal cord and brain injuries.